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Three site-directed mutants of human epidermal growth factor, Leu-26+Gly, Leu-47-+Ala, and Be-23-+Thr, were examined for their ability to 
stimulate the protein-tyrosine kinase activity of the epidermal growth factor receptor. The receptor binding atiinities of the mutant growth factors 
were 20- to 50-fold lower, as compared to wild-type growth factor. At saturating concentrations of growth factor, the velocities of the phosphoryla- 
tion of exogenously added substrate and receptor autophosphorylation were significantly lower with the mutant analogs, suggesting a partial ‘un- 
coupling’ of signal transduction. The mutant analogs were shown to compete directly with the binding of wild-type, resulting in a decrease in growth 
factor-stimulated kinase activity. 
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1. INTRODUCTION 
EGF is one of the most highly studied growth fac- 
tors, yet much remains to be learned about its 
mechanism of action. The biological effects of EGF are 
initiated by interaction with its specific cell-surface 
receptor (see [1,2] for reviews). The binding of EGF to 
the receptor’s extracellular domain stimulates the 
receptor’s cytoplasmically located protein-tyrosine 
kinase which can phosphorylate itself as well as other 
cellular proteins [3,4]. The process by which kinase ac- 
tivation is achieved has been explained as resulting 
either from dimerization of inactive receptor 
monomers to form activated dimers 15-81 or from 
dissociation of latent receptor dimers to monomers 
having high tyrosine kinase activity [9]. A third model 
invokes a ligand-induced intramolecular conforma- 
tional change in the receptor’s extracellular domain 
leading to the activation of the kinase activity of the 
receptor [lo, 111. While this issue is still being resolved, 
it is quite clear that the tyrosine kinase activity of the 
receptor is essential for the mitogenic response of the 
cells to EGF [12,13]. 
Recently our laboratory has generated numerous 
Correspondence address: A. Stevens, Biology Division, Oak Ridge 
National Laboratory, PO Box 2009, Oak Ridge, TN 37831-8077, 
USA 
site-specific mutants of hEGF in an attempt to deter- 
mine the regions, and/or specific residues, involved in 
receptor binding ([14]; Campion, S.R., Matsunami, 
R.K., Engler, D.A. and Niyogi, SK., submitted for 
publication; Matsunami, R.K., unpublished observa- 
tions). The receptor-binding affinity of each mutant, 
relative to wild type, was measured by both radiorecep- 
tor competition and receptor tyrosine kinase stimula- 
tion assays. The values obtained by the two methods 
were generally in agreement for each mutant, and mu- 
tant growth factors with relative affinities ranging from 
180% to less than 1% have been produced. In this com- 
munication we describe three mutants of hEGF, name- 
ly, Leu-26 + Gly, Leu-47 + Ala, and Ile-23 + Thr, 
which stimulate the receptor to a lower Vmax for the 
kinase reaction compared to that obtained with wild- 
type EGF using either (Glu4Tyri), as a substrate or by 
measuring autophosphorylation of the EGF receptor. 
These mutants are also demonstrated to inhibit com- 
petitively the activity of wild-type hEGF in its stimula- 
tion of the protein-tyrosine kinase activity of the 
receptor. Such mutants are interesting in that the lower 
V,,, may indicate an altered receptor-ligand complex, 
making it less active. These mutant hEGFs might be 
potentially important as growth inhibitors that could 
block the action of wild type hEGF. 
2. MATERIALS AND METHODS 
Abbreviutions: EGF, epidermal growth factor; hEGF, human epider- 
ma1 growth factor; DTT, 1,Cdithiothreitol; WGA, wheat germ ag- 
glutinin; HPLC, high pressure liquid chromatography; V,,,,,, 
maximum velocity of a reaction; SDS, sodium dodecyl sulfate 
2.1. Materials 
[Y-~‘P]ATP (4500 Ci/mmol) was purchased from ICN Radio- 
chemicals and (GluoTyrr), from Sigma Chemical Company. 
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Fig. 1. Dose-response curves for stimulation of EGF receptor tyrosine-kinase activity by mutant EGFs, and competition plots for each of the 
mutants. l Dose-response curves; A actual and A theoretical competition curves against 4.5 nM wild type; 0 actual and n theoretical com- 
petition curves against 60 nM wild type; o actual and l theoretical competition curves against 75 nM wild type. The receptor tyrosine-kinase 
assays were done as described in section 2. 
2.2. Production and purification of EGF mutant proteins 
Recombinant wild-type hEGF was made and isolated as reported 
previously 1141. EGF mutants were generated by site-directed 
mutagenesis using a modified Ml3 primer extension method [14]. 
Purification was the same as that for wild-type hEGF. 
2.3. Isolation of membranes and purification of receptors 
Membrane fractions were isolated from confluent A431 cells and 
the EGF receptor was solubilized and purified on a WGA agarose 
column as described previously [14]. 
2.4. Competition binding assay 
The binding affinity of each mutant protein was measured by its 
ability to compete with [“‘I]hEGF in binding to A431 membrane 
fractions. Conditions of the binding assay and a description of the 
determination of dissociation constants have been reported pre- 
viously [14]. 
2.5 Kinase assay 
The activity of each hEGF protein in the protein-tyrosine kinase 
reaction was measured by its ability to stimulate the phosphorylation 
of a synthetic polymer, (Glu4Tyri),, of average molecular mass 
35 000. Previous studies have shown that the polymer is a good 
substrate for the EGF receptor’s protein-tyrosine kinase [15,16]. The 
assay procedure, similar to that of Koland and Cerione [ 111, was the 
same as used by Engler et al. [14] and binding affinities were deter- 
mined as described in the same report. Competition kinase assays 
were carried out by keeping the concentration of the wild-type pro- 
tein constant while that of the mutant was varied, as shown in Fig. 1. 
Each point shown on the curves is an average value determined from 
duplicate experiments. Analysis of the time courses of the reactions 
with wild-type hEGF and the mutants showed that they were linear. 
2.6 SDS gel electrophoresis of the kinase reaction mixtures 
To measure the extent of autophosphorylation of the EGF recep- 
tor, kinase reactions were performed as described above, with the 
following modifications: (Glu4Tyri), substrate was not added, the 
specific activity of [y-32P]ATP was 1 Ci/mmol, and the reactions 
were stopped by the addition of 3 x Laemmli loading buffer [17]. 
The samples were then electrophoresed according to the procedure of 
Laemmli [17]. The amount of each EGF protein used in the 
autophosphorylation assay was the amount that was saturating as 
determined from the kinase assay using the (Glu4Tyri), substrate. 
The gel was stained, dried, and processed for autoradiography. The 
autoradiograph was then scanned using a laser densitometer to deter- 
mine the amount of radioactivity incorporated into the EGF receptor 
band. Greater than 95% of the radioactivity on the gel was associated 
with a 170 kDa band, which was assumed to be the EGF receptor. 
Each reaction was done in duplicate and the average of the two values 
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obtained by densitometry scans was used to calculate the values 
shown in Table II. 
3. RESULTS AND DISCUSSION 
The relative receptor binding affinities of the three 
mutants of hEGF described in this paper are shown in 
Table I. The values were obtained by using the 
radioreceptor competition assay and by measuring their 
stimulation of the receptor protein-tyrosine kinase ac- 
tivity. Both assays show that the Be-23 + Thr and 
Leu-26 -+ Gly mutants have about 5% of the binding 
Table I 
Receptor binding affinities of hEGF species as measured by 
radioreceptor competition and receptor tyrosine kinase stimulation 
hEGF species 
Relative binding affinity (Ore of wildtype) 
Radioreceotor Tvrosine kinase 
competition assaya stimulation assayb 
Wild type 100 100 
Leu-26-+Gly 5 4 
Leu-47+Ala 2 2 
Ile-23 -t Thr 3 5 
aRelative binding affinity = I& (wild type)/ICse (mutant) x lOO%, 
as described prevously [14]. 
bRelative binding affinity = ECso (wild type)/E&, (mutant) x 
lOO%, as described previously [14]. 
Table II 
I’,,,., values obtained for stimulation of the receptor tyrosine-kinase 
by hEGF analogs 
I’,,,, of receptor tyrosine kinase 
(Vo of wild type) 
hEGF species (Gly~Tyri), Receptor 
as substrate autophosphorylation 
Wild type 100 100 
Leu-26-+Gly 22 23 
Leu-47+Ala 24 17 
Ile-23-+Thr 31 38 
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affinity of wild type, as determined from the EC50 
values of the dose response curves, while the 
Leu-47 + Ala mutant has only about 2% of wild type. 
Despite their lower binding affinities, each mutant was 
able to fully displace wild-type hEGF in the competi- 
tion binding assay, indicating that the mutants bound 
to the receptor in a specific manner. 
As shown in Table II, the I’,,,,, of the receptor 
tyrosine kinase activity was markedly less with the three 
mutants than that obtained with wild-type hEGF. 
Values, relative to wild-type, were 22% for the 
Leu-26 + Gly mutant, 24% for the Leu-47 + Ala mu- 
tant, and 31% for the Ile-23 -+ Thr mutant, in the 
kinase reaction in which (GltiTyrl),, was used as a 
substrate. 
The velocity of the EGF receptor autophosphoryla- 
tion reaction was also measured at saturating concen- 
trations of each mutant. The results show that 
autophosphorylation of the EGF receptor was 
significantly lower when stimulated by the mutant 
hEGFs as compared with wild-type hEGF. The 
Leu-26 -+ Gly mutant stimulated autophosphorylation 
of the EGF receptor band (170 kDa) 23% that of wild- 
type, the Leu-47 --t Ala mutant 17% of wild-type, and 
the Ile-23 + Thr, 38% (Table II). These values are 
similar to the V,,, values obtained with the (GludTyr& 
substrate. 
It was decided to examine whether the hEGF mutant 
proteins, having lower stimulatory capacity as 
demonstrated in the receptor protein-tyrosine kinase 
assay, would act as competitive inhibitors of wild-type 
hEGF under the kinase assay conditions. A modifica- 
tion of the equation from Segel [18] for the velocity of 
a reaction with one enzyme and mixed alternative 
substrates was used to evaluate the competitive nature 
of the mutant hEGF analogs: 
Vt = I/,,,,(tA]/KdA) + &,x&B]/&,) 
I + [A]/&, + [B]/&, 
where A and B are two different activators, and vmaxA 
is the maximum velocity of the reaction with A as the 
activator, and vmaxg is the maximum velocity of the 
reaction with B as the activator, K+, and Kdg are the 
equilibrium constants for activators A and B, respec- 
tively, and vt is the observed velocity under the given 
conditions. 
Fig. 1, panels A, B and C, show the dose-response 
curves for stimulation by mutant hEGFs of the receptor 
tyrosine kinase with (Gly4Tyr&, as a substrate and the 
competition plots for each of the mutants at two dif- 
ferent concentrations of wild-type hEGF. Equilibrium 
constants and velocity values were obtained from the 
concentration curves. Also plotted are the theoretical 
curves predicted by the above equation using the values 
obtained for the individual mutants. These theoretical 
curves closely resemble the actual curves and 
demonstrate that the inhibitory nature of the mutant 
analogs is purely competitive. A mutant hEGF, 
Tyr-22 + Asp, that has a lower relative binding affini- 
ty (25% that of wild type) but not a lower I/m=, was 
tested as a competitor against wild-type hEGF. The 
competition by this mutant as predicted by the equation 
resulted in no inhibition of activity (data not shown). 
The competitive inhibition of wild-type hEGF- 
stimulated tyrosine-kinase activity by the mutant hEGF 
species confirms their lower stimulatory capacity. 
These results clearly demonstrate a partial ‘uncoupling’ 
of growth factor binding and kinase stimulation. The 
observed decrease in the maximal rate of phosphoryla- 
tion catalyzed by the EGF/receptor complex in 
response to the mutant hEGF species suggests that the 
activated receptor-growth factor complexes formed 
with these mutants have a conformation somewhat 
altered from the complex formed with the wild-type 
growth factor. Obviously, physicochemical studies are 
necessary to determine the nature of the conforma- 
tional change(s). Studies examining the structure of the 
complexes formed between the EGF analogs and the 
external domain of the EGF receptor as described by 
Greenfield et al. [19] for wild-type EGF may provide 
evidence of altered receptor conformations. Our find- 
ings also suggest hat the design of growth-inhibitory 
EGF analogs may be feasible. 
Acknowledgments: The authors thank Drs John S. Cook and Melin- 
da R. Hauser for critical reading of the manuscript. This research was 
supported by the Office of Health and Environmental Research, 
United States Department of Energy under Contract DE-ACOS- 
840121400 with the Martin Marietta Energy Systems, Inc. A 
preliminary account of this work was presented at the Joint Meeting 
of the American Society for Cell Biology and the American Society 
for Biochemistry and Molecular Biology [Campion, S.R., Mat- 
Sunami, R.K., Engler, D.A., Stevens, A. and Niyogi, S.K. (1988) J. 
Cell Biol. 107,695al. R.K.M. was supported by National Cancer In- 
stitute Predoctoral Training Grant CA 09104. S.R.C. was supported 
by National Cancer Institute Postdoctoral Training Grant CA 09336. 
REFERENCES 
u1 
121 
[31 
141 
VI 
161 
[71 
1’31 
PI 
IlO1 
Carpenter, G. and Cohen, S. (1987) Annu. Rev. Biochem. 56, 
881-914. 
Yarden, Y. and Ullrich, A. (1988) Annu. Rev. Biochem. 57, 
443-478. 
Basu, M., Biswas, R. and Das, M. (1984) Nature 311,477-480. 
Schlessinger, J. (1986) J. Cell. Biol. 103, 2067-2072. 
Yarden, Y. and Schlessinger, J. (1987) Biochemistry 26, 
1434-1442. 
Yarden, Y. and Schlessinger, J. (1987) Biochemistry 26, 
1443-1451. 
Schlessinger, J. (1988) Trends Biochem. Sci. 13, 443-447. 
Biini-Schnetzler, M. and Pilch, P.F. (1987) Proc. Natl. Acad. 
Sci. USA 84, 7832-7836. 
Biswas, R., Basu, M., Sen-Majumdar, A. and Das, M. (1985) 
Biochemistry 24, 3795-3802. 
Staros, J.V., Cohen, S. and Russo, M.W. (1985) in: Molecular 
Mechanisms of Transmembrane Signalling (Cohen, P. and 
Housley, M.D. eds) pp. 253-278, Elsevier, Amsterdam. 
107 
Volume 264, number 1 FEBS LETTERS May 1990 
[ll] Koland, J.G. and Cerione, R.E. (1988) J. Biol. Chem. 263, [15] Braun, S., Raymond, W.E. and Racker, E. (1984) J. Biol. 
2230-2237. Chem. 259, 2051-2054. 
[12] Chen, W.S., Lazar, C.S., Poenie, M., Tsien, R.Y., Gill, G.N. 
and Rosenfeld, M.G. (1987) Nature 328, 820-823. 
[13] Honegger, A.M., Szapary, D., Schmidt, A., Lyall, R., Van 
Obberghen, E., Dull, T.J., Ullrich, A. and Schlessinger, J. 
(1987) Mol. Cell Biol. 7, 4568-4571. 
[14] Engler, D.A., Matsunami, R.K., Campion, S.R., Stringer, 
C.D., Stevens, A. and Niyogi, S.K. (1988) J. Biol. Chem. 263, 
12384-12390. 
[16] Zick, Y., Grunberger, G., Rees-Jones, R.W. and Comi, R.J. 
(1985) Eur. J. Biochem. 148, 177-182. 
[17] Laemmli, U.K. (1970) Nature 227, 680-685. 
[IS] Segel, I.H. (1975) in: Enzyme Kinetics, Wiley, New York. 
[19] Greenfield, C., Hiles, I., Waterfield, M.D., Federwisch, M., 
Wollmer, A., Blundell, T.L. and McDonald, N. (1989) EMBO 
J. 8, 4115-4123. 
108 
